HC Wainwright & Co. Reiterates Buy on NovoCure, Maintains $115 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar reiterates a Buy rating on NovoCure (NASDAQ:NVCR) and maintains a $115 price target.
June 06, 2023 | 2:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Emily Bodnar reiterates a Buy rating on NovoCure and maintains a $115 price target.
The reiterated Buy rating and maintained price target of $115 by HC Wainwright & Co. analyst Emily Bodnar indicates a positive outlook for NovoCure's stock in the short term. This news is directly related to NVCR and is important for investors as it reflects the analyst's confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100